Johnson & Johnson beat expectations for quarterly earnings and raised its dividend payouts to shareholders on Tuesday, while reporting $100 million in sales of its COVID-19 vaccine, whose use was paused by U.S. regulators last week.
The company, which has previously said the vaccine will be available on a not-for-profit basis until the end of the pandemic, also tightened its forecast for adjusted profit this year, suggesting it was largely performing as previously expected.
